Dutasteride |
| Catalog No.GC10893 |
5-alpha-reductase inhibitor
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 164656-23-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Dutasteride (Avodart) is an inhibitor of dual 5-alpha-reductase for treating benign prostatic hyperplasia (BPH).
Dutasteride has been reported to inhibit conversion of 3H-testosterone to 3H-DHT by more than 99% in LNCaP cells. Dutasteride strongly reduces growth, proliferation, and viability of LNCaP cells as well. Dutasteride increased the enzymatic activities of caspase 7 and caspase 8 dose-dependently at 48 hours, providing functional significance and confirming that the apoptotic and survival pathways are being activated by dutasteride treatment in LNCaP cells [1].
In vivo, dutasteride, which inhibits both 5αR1/5αR2, is efficacious in blocking prostate cancer development or progression in C57BL/6 TRAMP x FVB mice [2].
References:
[1] Schmidt LJ1, Murillo H, Tindall DJ. Gene expression in prostate cancer cells treated with the dual 5 alpha-reductase inhibitor dutasteride. J Androl. 2004 Nov-Dec;25(6):944-53.
[2] Opoku-Acheampong AB1, Unis D, Henningson JN, Beck AP, Lindshield BL.Preventive and therapeutic efficacy of finasteride and dutasteride in TRAMP mice. PLoS One. 2013 Oct 18;8(10):e77738. doi: 10.1371/journal.pone.0077738. eCollection 2013.
Average Rating: 5 (Based on Reviews and 26 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *